STOCK TITAN

Pure Bioscience Stock Price, News & Analysis

PURE OTC Link

Company Description

PURE Bioscience, Inc. (PURE) is a manufacturing company that focuses on developing and commercializing proprietary antimicrobial products. According to company disclosures, its technology platform is based on patented, stabilized ionic silver, and its products contain silver dihydrogen citrate (SDC), described as a broad-spectrum, non-toxic antimicrobial agent that formulates well with other compounds. PURE’s products are used primarily in the food and beverage industry to address sanitation, disinfection, and hygienic control challenges.

Core technology and products

PURE describes SDC as a platform technology distinguished from existing products in the marketplace by its superior efficacy, reduced toxicity, and mitigation of bacterial resistance. Company materials explain that SDC kills microorganisms through two modes of action: silver ions deactivate structural and metabolic membrane proteins, and microbes take up SDC as a food source, allowing silver ions to enter and denature DNA, which halts replication. The company states that SDC is a stabilized silver ion complex with a shelf life of several years.

PURE highlights several SDC-based offerings in its communications. Its PURE Hard Surface product is described as a powerful food-contact sanitizer with broad-spectrum protection and the lowest EPA toxicity rating, with no personal protective equipment required and no rinse required on food-contact surfaces when used as directed. The company also references a seasonal direct food-contact solution, PURE Control®, used to treat leafy greens destined for commercial sale. In addition, PURE has introduced SDC-powered sanitation technology and equipment for the transportation industry and has developed SDC-based membrane treatment solutions for dairy and beverage producers.

End markets and applications

Across multiple press releases, PURE states that it focuses primarily on food safety and the food and beverage industry. Its antimicrobial products are positioned to combat health and environmental challenges posed by pathogens and to help ensure hygienic control in food and beverage manufacturing environments. The company reports that PURE Hard Surface is used as a food-contact sanitizer and has been adapted for membrane treatment in dairy and beverage filtration systems, including ultrafiltration (UF) and reverse osmosis (RO) membranes. Company descriptions also note activity in the produce industry, where PURE Control is used on leafy greens, and in the transportation industry, where SDC-powered sanitation technology is offered to major trucking fleets through distribution partners.

Membrane treatment and dairy/beverage focus

PURE has placed particular emphasis on its SDC-based membrane treatment solution for dairy and beverage producers. Company communications describe this solution, using PURE Hard Surface, as addressing common membrane fouling and sanitization challenges. Reported attributes include the ability to remove fouling, restore flow and throughput, and delay membrane replacement without damaging or oxidizing membranes. The company cites results such as multi-log microbial reduction in short contact times, complete membrane penetration in minutes in RO systems, and restoration of throughput in UF systems, while maintaining sanitation to meet stringent quality specifications. PURE also notes that the treatment is NSF-listed for relevant applications and characterized as non-oxidizing, with benefits that include conserving water and energy, reducing Clean-In-Place cycle downtime, and prolonging membrane life.

Distribution and market access

PURE reports using a combination of direct customers and distribution partners to reach its end markets. It has announced multi-year distribution agreements for SDC products with organizations active in food processing and cleaning solutions. These include an agreement with Hydrite Chemical Company, described as a provider of solutions for food processing and other markets, and a distribution agreement with Bonsai, a California-based provider of American-made cleaning tools and solutions. Through Bonsai’s online platform, PURE states that its EPA-registered disinfectants and a complete line of cleaners and sanitizers are made available to small businesses and individual customers, in addition to larger manufacturers. The company also references collaboration with a California State University Dairy Pilot Processing Center to pilot UF and RO systems as part of scaling its membrane treatment solutions.

Corporate profile and trading

PURE Bioscience, Inc. is identified in its SEC filings and press releases as a U.S.-based corporation with a mailing address in El Cajon, California, in the San Diego County area. The company’s common stock trades on the OTCQB market under the ticker symbol PURE. SEC filings, including annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and proxy statements, provide details on its capital structure, stockholders’ equity (deficiency), and governance. A definitive proxy statement for the 2026 annual meeting describes the company’s plans to seek stockholder approval for an increase in authorized common shares and includes information on board composition, executive compensation, and auditor ratification.

Business model and financial reporting

In its financial disclosures, PURE reports revenue primarily from net product sales of its SDC-based antimicrobial products, with additional royalty revenue. The company’s press releases summarize results for fiscal periods, including net product sales, cost of goods sold, gross profit, operating expenses such as selling, general and administrative costs and research and development, and net loss. PURE has also discussed efforts to reduce personnel, facility, and board fees as part of managing operating expenses. Financing activities disclosed in cash flow statements include proceeds from convertible notes payable to related parties, which contribute to the company’s liquidity profile.

Strategic initiatives and branding

PURE has described steps to refine its identity and market positioning. It announced a rebranding campaign in collaboration with a design agency, Branded By Greenville, to renew its corporate vision and better reflect its focus on scientific advancements in antimicrobials and disinfection for the food and beverage industry. The company’s communications emphasize a mission centered on chemical safety, efficacy, and effectiveness, and on developing solutions that meet high safety standards for consumers and distributors. PURE also highlights ongoing research and development efforts and partnerships with academic and industry experts aimed at advancing SDC-based cleaning and sanitization solutions.

Governance and leadership

SEC filings and press releases provide information on PURE’s governance structure and leadership roles. A definitive proxy statement outlines the composition of the board of directors and the matters to be voted on at the annual meeting, including director elections and advisory votes on executive compensation. A current report on Form 8-K and related press release describe the appointment of a President in addition to existing responsibilities as Corporate Secretary, while the Chief Executive Officer continues as principal executive officer and a board member. The company indicates that executive officers participate in standard indemnification and compensation arrangements and that there are no disclosed family relationships or certain related-party arrangements requiring disclosure beyond those described in its filings.

Risk considerations and regulatory context

PURE’s press releases include forward-looking statements sections that reference risks and uncertainties related to its business. These statements note factors such as acceptance of the company’s products in the marketplace, the ability to convert evaluations of products like PURE Control and PURE Hard Surface into orders, maintenance of relationships with partners and distributors, the need to generate sufficient revenues and manage operating expenses to reach profitability, access to funding, development of new products and regulatory approvals, competitive dynamics, and dependence on third-party vendors for manufacturing. The company points investors to its periodic SEC reports, including Form 10-K and Form 10-Q filings, for detailed risk factor discussions and cautions against placing undue reliance on forward-looking statements.

Stock Performance

$0.0830
+1.47%
+0.00
Last updated: March 25, 2026 at 15:25
-9.11%
Performance 1 year

Pure Bioscience (PURE) stock last traded at $0.0818, up 1.47% from the previous close. Over the past 12 months, the stock has lost 9.1%. At a market capitalization of $9.2M, PURE is classified as a micro-cap stock with approximately 111.9M shares outstanding.

Latest News

Pure Bioscience has 10 recent news articles. Of the recent coverage, 3 articles coincided with positive price movement and 6 with negative movement. Key topics include earnings, partnership. View all PURE news →

SEC Filings

Pure Bioscience has filed 5 recent SEC filings, including 2 Form 8-K, 1 Form 10-Q, 1 Form DEF 14A, 1 Form PRE 14A. The most recent filing was submitted on March 17, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all PURE SEC filings →

Financial Highlights

$2.2M
Revenue (TTM)
-$2.4M
Net Income (TTM)
-$2.0M
Operating Cash Flow

Pure Bioscience generated $2.2M in revenue over the trailing twelve months, retaining a 59.3% gross margin, operating income reached -$2.3M (-103.4% operating margin), and net income was -$2.4M, reflecting a -109.1% net profit margin. Diluted earnings per share stood at $-0.02. The company generated -$2.0M in operating cash flow. With a current ratio of 0.37, short-term liquidity bears monitoring.

Upcoming Events

JUL
01
July 1, 2026 - September 30, 2026 Product

PURE Clean Q3 launch

USDA Biobased-certified PURE Clean; launch and pre-order fulfillment planned; details TBA

Pure Bioscience has 1 upcoming scheduled event. The next event, "PURE Clean Q3 launch", is scheduled for July 1, 2026 (in 98 days). Investors can track these dates to stay informed about potential catalysts that may affect the PURE stock price.

Short Interest History

Last 12 Months

Short interest in Pure Bioscience (PURE) currently stands at 2.9 thousand shares, up 0.9% from the previous reporting period, representing 0.0% of the float. Over the past 12 months, short interest has decreased by 85.2%. This relatively low short interest suggests limited bearish sentiment.

Days to Cover History

Last 12 Months

Days to cover for Pure Bioscience (PURE) currently stands at 1.0 days. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed. The ratio has shown significant volatility over the period, ranging from 1.0 to 3.4 days.

PURE Company Profile & Sector Positioning

Pure Bioscience (PURE) operates in the Household & Personal Products industry within the broader Consumer Defensive sector and is listed on the OTC Link.

Investors comparing PURE often look at related companies in the same sector, including Cca Industries (CAWW), Sentient Brands Hldgs Inc (SNBH), Skinvisible (SKVI), Naples Soap Company Ord Shs (NASO), and Bemax (BMXC). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate PURE's relative position within its industry.

Frequently Asked Questions

What is the current stock price of Pure Bioscience (PURE)?

The current stock price of Pure Bioscience (PURE) is $0.0818 as of March 24, 2026.

What is the market cap of Pure Bioscience (PURE)?

The market cap of Pure Bioscience (PURE) is approximately 9.2M. Learn more about what market capitalization means .

What is the revenue (TTM) of Pure Bioscience (PURE) stock?

The trailing twelve months (TTM) revenue of Pure Bioscience (PURE) is $2.2M.

What is the net income of Pure Bioscience (PURE)?

The trailing twelve months (TTM) net income of Pure Bioscience (PURE) is -$2.4M.

What is the earnings per share (EPS) of Pure Bioscience (PURE)?

The diluted earnings per share (EPS) of Pure Bioscience (PURE) is $-0.02 on a trailing twelve months (TTM) basis. Learn more about EPS .

What is the operating cash flow of Pure Bioscience (PURE)?

The operating cash flow of Pure Bioscience (PURE) is -$2.0M. Learn about cash flow.

What is the profit margin of Pure Bioscience (PURE)?

The net profit margin of Pure Bioscience (PURE) is -109.1%. Learn about profit margins.

What is the operating margin of Pure Bioscience (PURE)?

The operating profit margin of Pure Bioscience (PURE) is -103.4%. Learn about operating margins.

What is the gross margin of Pure Bioscience (PURE)?

The gross profit margin of Pure Bioscience (PURE) is 59.3%. Learn about gross margins.

What is the current ratio of Pure Bioscience (PURE)?

The current ratio of Pure Bioscience (PURE) is 0.37, indicating the company's ability to pay short-term obligations. Learn about liquidity ratios.

What is the gross profit of Pure Bioscience (PURE)?

The gross profit of Pure Bioscience (PURE) is $1.3M on a trailing twelve months (TTM) basis.

What is the operating income of Pure Bioscience (PURE)?

The operating income of Pure Bioscience (PURE) is -$2.3M. Learn about operating income.

What does PURE Bioscience, Inc. do?

PURE Bioscience, Inc. develops and commercializes proprietary antimicrobial products based on patented, stabilized ionic silver. Its products contain silver dihydrogen citrate (SDC), a broad-spectrum, non-toxic antimicrobial agent used primarily in the food and beverage industry for sanitation, disinfection, and hygienic control.

What is silver dihydrogen citrate (SDC) and why is it important to PURE?

Silver dihydrogen citrate (SDC) is the core active ingredient in PURE’s antimicrobial technology platform. The company describes SDC as a stabilized silver ion complex that kills microorganisms by deactivating membrane proteins and denaturing microbial DNA, offering broad-spectrum efficacy, reduced toxicity, and mitigation of bacterial resistance, with a shelf life of several years.

Which industries does PURE Bioscience primarily serve?

According to its public statements, PURE focuses primarily on the food and beverage industry and food safety applications. It reports activity in produce, dairy, beverage manufacturing, and transportation, where its SDC-based products are used for sanitation, disinfection, and membrane treatment.

What is PURE Hard Surface?

PURE Hard Surface is described by the company as a flagship SDC-based food-contact sanitizer. It offers broad-spectrum antimicrobial protection, carries the lowest EPA toxicity rating, requires no personal protective equipment and no rinse on food-contact surfaces when used as directed, and has been adapted for applications such as membrane treatment in dairy and beverage filtration systems.

What is PURE Control and how is it used?

PURE reports that PURE Control is a seasonal direct food-contact solution based on its SDC technology. The company states that PURE Control is used to treat leafy greens destined for commercial sale, representing an application of its antimicrobial platform in the produce segment of the food industry.

How does PURE’s membrane treatment solution support dairy and beverage producers?

PURE has developed an SDC-based membrane treatment solution, using PURE Hard Surface, for ultrafiltration and reverse osmosis systems in dairy and beverage operations. Company materials state that this treatment removes fouling, restores throughput, sanitizes membranes without oxidation or damage, conserves water and energy, and can extend membrane life while meeting stringent quality specifications.

How does PURE Bioscience bring its products to market?

PURE describes a go-to-market approach that includes direct customers and distribution partners. It has announced multi-year distribution agreements with organizations such as Hydrite Chemical Company and Bonsai, which help expand access to its SDC-based disinfectants, cleaners, and sanitizers across food processing, dairy, and other markets, including online channels for small businesses and individual customers.

On which market is PURE Bioscience stock traded and under what symbol?

Company press releases identify PURE Bioscience, Inc. as trading on the OTCQB market under the ticker symbol PURE. SEC filings and investor communications use this symbol in connection with its common stock.

What are the main revenue sources for PURE Bioscience?

In its financial disclosures, PURE reports revenue primarily from net product sales of its SDC-based antimicrobial products, with additional royalty revenue. Its statements of operations detail total revenue, cost of goods sold, gross profit, operating expenses, and net loss for each reporting period.

Where can investors find more detailed information about PURE Bioscience?

Investors can review PURE Bioscience’s SEC filings, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and proxy statements. These documents provide detailed information on financial results, risk factors, governance, capital structure, and matters submitted to stockholders.